| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SNX10 |
| Uniprot No | Q9Y5X0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-201 aa |
| 活性数据 | MFPEQQKEEF VSVWVRDPRI QKEDFWHSYI DYEICIHTNS MCFTMKTSCV RRRYREFVWL RQRLQSNALL VQLPELPSKN LFFNMNNRQH VDQRRQGLED FLRKVLQNAL LLSDSSLHLF LQSHLNSEDI EACVSGQTKY SVEEAIHKFA LMNRRFPEED EEGKKENDID YDSESSSSGL GHSSDDSSSH GCKVNTAPQE S |
| 分子量 | 23.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人SNX10蛋白的参考文献示例(仅供参考，具体文献需根据实际数据库查询)：
---
1. **文献名称**：*"SNX10 mediates osteoclastogenesis by regulating lysosomal membrane stability"*
**作者**：Akerstrom et al. (2015)
**摘要**：研究揭示了SNX10通过调控溶酶体膜的稳定性在破骨细胞分化中的关键作用，实验中利用重组人SNX10蛋白验证其与溶酶体酸化相关的功能。
2. **文献名称**：*"Structural insights into SNX10-mediated membrane remodeling in endosomal trafficking"*
**作者**：Chen et al. (2018)
**摘要**：通过X射线晶体学解析了重组人SNX10蛋白的结构，阐明其BAR结构域如何参与膜变形及内体运输的分子机制。
3. **文献名称**：*"SNX10 deficiency disrupts autophagic flux and promotes tumor progression"*
**作者**：Wang et al. (2020)
**摘要**：研究表明SNX10缺失通过干扰自噬通路促进癌症进展，实验中使用重组SNX10蛋白恢复功能，证实其在自噬体-溶酶体融合中的作用。
4. **文献名称**：*"Role of SNX10 in lysosomal storage disorders: Implications for therapeutic strategies"*
**作者**：Reyes et al. (2022)
**摘要**：探讨SNX10突变与溶酶体贮积症的关系，重组SNX10蛋白的体外递送可部分挽救溶酶体功能，为基因治疗提供依据。
---
**注意**：以上为模拟示例，建议通过PubMed、Google Scholar等平台以“SNX10”、“recombinant SNX10”等关键词检索真实文献。
**Background of Recombinant Human SNX10 Protein**
The Sorting Nexin 10 (SNX10) protein belongs to the sorting nexin family, a group of phosphoinositide-binding proteins involved in membrane trafficking, endosomal sorting, and cellular signaling. SNX10 is characterized by a conserved Phox homology (PX) domain, which facilitates interactions with lipid membranes, particularly phosphatidylinositol phosphates. It localizes to early endosomes and plays a critical role in regulating vesicular transport, lysosomal function, and autophagy.
SNX10 is notably linked to osteoclast maturation and bone homeostasis. Studies highlight its role in modulating proton secretion during bone resorption via interactions with vacuolar ATPase (V-ATPase). Dysregulation of SNX10 is associated with osteopetrosis and osteoporosis, underscoring its importance in skeletal health. Additionally, SNX10 has been implicated in cancer progression, influencing processes like angiogenesis and tumor cell invasion.
Recombinant human SNX10 protein, produced through heterologous expression systems (e.g., *E. coli* or mammalian cells), retains functional properties for *in vitro* studies. It is widely used to investigate molecular mechanisms of intracellular trafficking, autophagy-lysosomal pathways, and disease-related mutations. Its application extends to drug discovery, particularly in targeting bone disorders and cancers. Ongoing research focuses on elucidating SNX10's structural dynamics and signaling networks, aiming to harness its therapeutic potential.
×
